KILITCH DRUGS INDIA LTD (KILITCH) financials

KILITCH DRUGS INDIA LTD (KILITCH) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]

Market Cap: ₹806Cr.
Current Price: ₹230
Stock P/E: 24.7
ROE: 9.49%
ROCE: 11.4%
Book Value: ₹95.2
Dividend Yield: 0.00%
52W High / Low: ₹268/117

In Jun 2026, KILITCH DRUGS INDIA LTD (KILITCH) reported sales ₹40.91 Cr and net profit ₹5.05 Cr.

Annual TTM: sales ₹195 Cr, net profit ₹33 Cr.

Shareholding: Promoters 63.77% (Sep 2026), FIIs 0.10% (Sep 2026), DIIs 0.50% (Sep 2026), Public 35.62% (Sep 2026), No. of Shareholders 12,319% (Sep 2026).

KILITCH quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	45.35	46.51	56.30	34.12	37.81	44.67	71.97	40.91
Expenses	39.76	38.40	42.39	30.55	34.14	38.95	52.50	36.26
Operating Profit	5.59	8.11	13.91	3.57	3.67	5.72	19.47	4.65
OPM %	12.33%	17.44%	24.71%	10.46%	9.71%	12.81%	27.05%	11.37%
Other Income	5.81	2.37	2.32	3.50	7.61	1.61	1.14	3.55
Interest	0.42	0.49	0.72	0.59	0.68	0.60	0.58	0.49
Depreciation	0.40	0.47	0.51	0.50	0.53	0.56	0.70	0.76
Profit before tax	10.58	9.52	15.00	5.98	10.07	6.17	19.33	6.95
Tax %	16.35%	27.73%	24.20%	19.90%	13.51%	20.75%	27.57%	27.19%
Net Profit	8.85	6.88	11.37	4.79	8.72	4.89	14.00	5.05
EPS in Rs	2.53	1.97	3.25	1.37	2.49	1.40	4.00	1.44
Raw PDF	—	—	—	—	—	—	—	—

KILITCH profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	61	70	105	118	132	182	189	195
Expenses	59	65	94	100	111	150	155	162
Operating Profit	2	5	11	17	20	31	33	34
OPM %	2.6%	8%	11%	15%	16%	17%	18%	17%
Other Income	6	4	5	5	6	14	14	14
Interest	1	1	1	1	2	2	3	2
Depreciation	1	1	1	1	1	2	2	3
Profit before tax	5	8	14	19	23	41	42	43
Tax %	15%	18%	24%	19%	25%	23%	22%	—
Net Profit	4	6	11	16	18	31	32	33
EPS in Rs	1.33	1.83	3.11	4.64	5.02	8.90	9.27	9.33
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	—

KILITCH balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	15	15	15	16	16	16	16	35
Reserves	136	136	147	162	180	207	237	298
Borrowings	9	13	15	20	22	31	49	88
Other Liabilities	12	10	18	34	35	33	56	78
Total Liabilities	172	174	196	232	252	287	358	499
Fixed Assets	8	8	7	14	15	16	20	20
CWIP	0	0	0	0	1	6	47	140
Investments	100	98	106	117	110	121	121	124
Other Assets	65	68	82	101	126	145	170	216
Total Assets	172	174	196	232	252	287	358	499

KILITCH cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	7	7	6	5	6	-3	15	12
Cash from Investing Activity	-22	-10	-5	-16	6	-9	-41	-96
Cash from Financing Activity	15	1	2	8	3	11	16	86
Net Cash Flow	0	-1	3	-3	15	0	-11	2
Free Cash Flow	6	6	6	-3	3	-9	-32	-83
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	68%	596%	134%	70%	60%	22%	76%	69%

KILITCH shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	69.23%	69.23%	69.23%	63.77%	63.77%	63.77%	63.77%	63.77%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.12%	0.10%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.50%
Public	30.76%	30.77%	30.77%	36.22%	36.23%	36.22%	36.11%	35.62%
No. of Shareholders	10,139	9,749	10,379	10,929	12,043	11,785	12,627	12,319

KILITCH key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	88	102	120	144	165	171	168	227
Inventory Days	33	57	34	30	13	22	61	47
Days Payable	38	81	127	168	180	144	188	280
Cash Conversion Cycle	83	78	27	6	-3	49	40	-6
Working Capital Days	42	20	-15	-21	4	25	57	71
ROCE %	12%	3%	4%	7%	9%	10%	13%	11%

KILITCHUpdated 18 Oct 2026, 9:27

Kilitch Drugs India Ltd

KILITCHUpdated 18 Oct 2026, 9:27

Market Cap

₹806Cr.

Current Price

₹230

High / Low

₹268/117

Stock P/E

24.7

ROE9.49%

ROCE11.4%

Book Value₹95.2

Face Value₹10.0

Dividend Yield0.00%

About

Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	31.12	0.38	25.88	0.98	0.26	5.58	25.09	4.19	1.24
Sep 2023	31.57	0.55	25.73	0.92	0.28	5.93	28.5	4.24	1.21
Dec 2023	29.77	0.53	25.76	3.4	0.3	6.58	16.41	5.5	1.57
Mar 2024	39.14	0.44	33.93	0.9	0.41	5.26	30.8	3.64	1.04
Jun 2024	33.42	0.49	30.2	3.21	0.35	5.59	27.55	4.05	1.16
Sep 2024	45.35	0.42	39.76	5.81	0.4	10.58	16.35	8.85	2.53
Dec 2024	46.51	0.49	38.4	2.37	0.47	9.52	27.73	6.88	1.97
Mar 2025	56.3	0.72	42.39	2.32	0.51	15	24.2	11.37	3.25
Jun 2025	34.12	0.59	30.55	3.5	0.5	5.98	19.9	4.79	1.37
Sep 2025	37.81	0.68	34.14	7.61	0.53	10.07	13.51	8.72	2.49
Dec 2025	44.67	0.6	38.95	1.61	0.56	6.17	20.75	4.89	1.4
Mar 2026	71.97	0.58	52.5	1.14	0.7	19.33	27.57	14	4
Jun 2026	40.91	0.49	36.26	3.55	0.76	6.95	27.19	5.05	1.44

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	19	0	21	3	2	-1	-79	0	-0.07
Mar 2016	21	0	24	2	2	-2	-18	-2	-0.71
Mar 2017	27	0	27	1	1	0	-91	0	-0.01
Mar 2018	50	0	44	3	1	7	13	6	2.07
Mar 2019	96	1	79	4	1	20	24	15	4.42
Mar 2020	61	1	59	6	1	5	15	4	1.33
Mar 2021	70	1	65	4	1	8	18	6	1.83
Mar 2022	105	1	94	5	1	14	24	11	3.11
Mar 2023	118	1	100	5	1	19	19	16	4.64
Mar 2024	132	2	111	6	1	23	25	18	5.02
Mar 2025	182	2	150	14	2	41	23	31	8.9
Mar 2026	189	3	155	14	2	42	22	32	9.27
TTM	195	2	162	14	3	43	—	33	9.33

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	63.77%
FIIs	0.1%
DIIs	0.5%
Public	35.62%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	69.23%	0%	0%	30.76%
Mar 2024	69.23%	0%	0%	30.77%
Jun 2024	69.23%	0%	0%	30.77%
Sep 2024	69.23%	0%	0%	30.77%
Dec 2024	69.23%	0%	0%	30.76%
Mar 2025	69.23%	0%	0%	30.77%
Jun 2025	69.23%	0%	0%	30.77%
Sep 2025	63.77%	0%	0%	36.22%
Dec 2025	63.77%	0%	0%	36.23%
Mar 2026	63.77%	0%	0%	36.22%
Jun 2026	63.77%	0.12%	0%	36.11%
Sep 2026	63.77%	0.1%	0.5%	35.62%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	13	107	0	7	127	9	0	72	46	127
Mar 2016	13	105	0	8	126	8	0	92	25	126
Mar 2017	13	106	1	10	130	8	0	96	26	130
Mar 2018	14	117	1	13	145	7	0	101	37	145
Mar 2019	15	136	9	12	172	8	0	100	65	172
Mar 2020	15	136	13	10	174	8	0	98	68	174
Mar 2021	15	147	15	18	196	7	0	106	82	196
Mar 2022	16	162	20	34	232	14	0	117	101	232
Mar 2023	16	180	22	35	252	15	1	110	126	252
Mar 2024	16	207	31	33	287	16	6	121	145	287
Mar 2025	16	237	49	56	358	20	47	121	170	358
Mar 2026	35	298	88	78	499	20	140	124	216	499

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	-8	-31	0	-39
Mar 2016	18	-20	0	-2
Mar 2017	1	-1	0	0
Mar 2018	-1	-2	6	2
Mar 2019	7	-22	15	0
Mar 2020	7	-10	1	-1
Mar 2021	6	-5	2	3
Mar 2022	5	-16	8	-3
Mar 2023	6	6	3	15
Mar 2024	-3	-9	11	0
Mar 2025	15	-41	16	-11
Mar 2026	12	-96	86	2

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	243	285	200	150	88	102	120	144	165	171	168	227
Inventory Days	124	110	84	39	33	57	34	30	13	22	61	47
Days Payable	123	152	183	108	38	81	127	168	180	144	188	280
Cash Conversion Cycle	244	243	101	82	83	78	27	6	-3	49	40	-6
Working Capital Days	196	230	122	98	42	20	-15	-21	4	25	57	71
ROCE %	-1%	-2%	-0%	5%	12%	3%	4%	7%	9%	10%	13%	11%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of KILITCH DRUGS INDIA LTD (KILITCH)?

The reported market capitalisation for KILITCH DRUGS INDIA LTD (KILITCH) is ₹806Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of KILITCH?

The current price shown for KILITCH DRUGS INDIA LTD (KILITCH) on Fincrux is ₹230 with a 52-week high/low of ₹268/117.

What is the P/E ratio of KILITCH DRUGS INDIA LTD (KILITCH)?

The stock P/E for KILITCH DRUGS INDIA LTD (KILITCH) is 24.7 on Fincrux, with ROE at 9.49% and ROCE at 11.4%.

What were KILITCH latest quarterly results?

For Jun 2026, KILITCH DRUGS INDIA LTD (KILITCH) reported sales ₹40.91 Cr and net profit ₹5.05 Cr (figures in ₹ crore unless noted).

What are KILITCH annual sales and net profit?

For TTM, KILITCH DRUGS INDIA LTD (KILITCH) shows sales of ₹195 Cr and net profit of ₹33 Cr on the Fincrux profit & loss statement.

Who owns KILITCH DRUGS INDIA LTD (KILITCH)?

Latest shareholding for KILITCH DRUGS INDIA LTD (KILITCH) on Fincrux: Promoters 63.77% (Sep 2026), FIIs 0.10% (Sep 2026), DIIs 0.50% (Sep 2026), Public 35.62% (Sep 2026), No. of Shareholders 12,319% (Sep 2026).

Where can I find KILITCH DRUGS INDIA LTD (KILITCH) financials?

KILITCH DRUGS INDIA LTD (KILITCH) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show KILITCH balance sheet and cash flow?

Yes. The KILITCH DRUGS INDIA LTD (KILITCH) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 9:27